ArticleAdvances in virology2012
Oncolytic virotherapy for hematological malignancies.
Article in Advances in virology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 37 citations in OpenAlex.
- Measles Virus-Based Genetic Modifications: Progress in Hematological Malignancy Treatment.OncoTargets and therapy · 2025Review
- Review
- Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity.Molecular cancer therapeutics · 2021Article
- Oncolytic Virotherapy and Microenvironment in Multiple Myeloma.International journal of molecular sciences · 2021Review
- Oncolytic Virus Therapy with HSV-1 for Hematological Malignancies.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Article
- Oncolytic Viruses and Hematological Malignancies: A New Class of Immunotherapy Drugs.Current oncology (Toronto, Ont.) · 2020Review
- Oncolytic Viruses and Immune Checkpoint Inhibitors: Preclinical Developments to Clinical Trials.International journal of molecular sciences · 2020Review
- Autologous Transplantation Using Donor Leukocytes LoadedMolecular therapy oncolytics · 2020Article
- Induction of Cell Death in the Human Acute Lymphoblastic Leukemia Cell Line Reh by Infection with Rotavirus Isolate Wt1-5.Biomedicines · 2020Article
- Oncolytic Virotherapy with Myxoma Virus.Journal of clinical medicine · 2020Review
- Antibody-Based Immunotherapeutic Strategies for the Treatment of Hematological Malignancies.BioMed research international · 2020Review
- Gene expression profiling of hematologic malignant cell lines resistant to oncolytic virus treatment.Oncotarget · 2017Article
- Gene and virotherapy for hematological malignancies.International journal of hematology · 2016Review
- NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy.Cancer immunology, immunotherapy : CII · 2016Review
- Myxoma Virus Induces Ligand Independent Extrinsic Apoptosis in Human Myeloma Cells.Clinical lymphoma, myeloma & leukemia · 2016Article
- Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic Strategies.Viruses · 2016Review
- Article
- Ex vivo virotherapy with myxoma virus does not impair hematopoietic stem and progenitor cells.Cytotherapy · 2016Article
- Systemic therapy with oncolytic myxoma virus cures established residual multiple myeloma in mice.Molecular therapy oncolytics · 2016Article
- Oncolytic myxoma virus: the path to clinic.Vaccine · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Hematological malignancies such as leukemias, lymphomas, multiple myeloma (MM), and the myelodysplastic syndromes (MDSs) primarily affect adults and are difficult to treat. For high-risk disease, hematopoietic stem cell transplant (HCT) can be used. However, in the setting of autologous HCT, relapse due to contamination of the autograft with cancer cells remains a major challenge. Ex vivo manipulations of the autograft to purge cancer cells using chemotherapies and toxins have been attempted. Because these past strategies lack specificity for malignant cells and often impair the normal hematopoietic stem and progenitor cells, prior efforts to ex vivo purge autografts have resulted in prolonged cytopenias and graft failure. The ideal ex vivo purging agent would selectively target the contaminating cancer cells while spare normal stem and progenitor cells and would be applied quickly without toxicities to the recipient. One agent which meets these criteria is oncolytic viruses. This paper details experimental progress with reovirus, myxoma virus, measles virus, vesicular stomatitis virus, coxsackievirus, and vaccinia virus as well as requirements for translation of these results to the clinic.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.